Original Publication Date: 1 December, 2014
Publication / Source: Future Oncology
Authors: Madappa Kundranda & Toufic Kachaamy
Pancreatic ductal adenocarcinoma is a lethal disease due to late diagnosis, early metastasis and the lack of effective therapies. In patients with metastatic disease, 1-year survival ranges from 17 to 23% and 5-year survival is less than 5%. This necessitates an urgent need for developing more effective therapies.